← Leaderboards
Mark Steven Cohen
University Of Kansas Lawrence
$1,514,123
Attributed
$2,887,233
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $463.3K · FY2009–25$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,887,233 · 3
By mechanism
R01$2,746,221 · 2
P20$141,012 · 1
Top collaborators
- Brian S J Blagg7 shared
Most similar at University Of Kansas Lawrence
Same institution · by research overlap
- Rick T Dobrowsky$8,170,709
- Vincent Crowley$379,204
- Marcus Laird Forrest$3,294,230
- Mary L. Michaelis$8,095,023
- Christer B Aakeroy$60,957
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorToxic EffectPharmaceutical PreparationsNanomolarMolecular ChaperonesMolecular ConformationNovel Anticancer DrugClientLeadNeoplastic CellExhibitsDoseAnalogEnzymesHepatotoxicityHeat-Shock ResponseBindingBinding SitesCancer TherapyCancer CellClinical TrialsIn VivoCell LineHsp 90 Inhibition
Grant awards (8)
Engineering the Next Generation of Safer Hsp90 Inhibitors$453,814
R01 · FY2025 · CA
Engineering the Next Generation of Safer Hsp90 Inhibitors$423,618
R01 · FY2024 · CA
Engineering the Next Generation of Safer Hsp90 Inhibitors$463,293
R01 · FY2023 · CA
Optimization and Investigation of Cruentaren A analogs$352,952
R01 · FY2021 · CA
Optimization and Investigation of Cruentaren A analogs$352,952
R01 · FY2020 · CA
Optimization and Investigation of Cruentaren A analogs$342,525
R01 · FY2019 · CA
Optimization and Investigation of Cruentaren A analogs$357,067
R01 · FY2017 · CA
NANOCARRIER BASED INTRALYMPHATIC IMAGING AND THERAPY FOR MELANOMA$141,012
P20 · FY2009 · RR · contact PI